Pazopanib
- Generic Name
- Pazopanib
- Brand Names
- Votrient
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23N7O2S
- CAS Number
- 444731-52-6
- Unique Ingredient Identifier
- 7RN5DR86CK
- Background
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
- Indication
Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
- Associated Conditions
- Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer
- Associated Therapies
- -
Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2021-04-15
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 43
- Registration Number
- NCT01636908
- Locations
- 🇳🇱
VUMedical Center, Amsterdam, Netherlands
Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy
- First Posted Date
- 2012-06-19
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT01622660
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-06-01
- Last Posted Date
- 2021-02-25
- Lead Sponsor
- Linda R Duska
- Target Recruit Count
- 148
- Registration Number
- NCT01610206
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸Maine Medical Center (MMP Women's Health), Scarborough, Maine, United States
🇺🇸Duke University, Durham, North Carolina, United States
Pazopanib in Second-line Therapy in Renal Cell Carcinoma
- First Posted Date
- 2012-04-16
- Last Posted Date
- 2014-03-12
- Lead Sponsor
- Associació per a la Recerca Oncologica, Spain
- Target Recruit Count
- 27
- Registration Number
- NCT01577784
- Locations
- 🇪🇸
Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
🇪🇸Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸Corporació Sanitaria Parc Taulí, Sabadell, Barcelona, Spain
Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2021-12-23
- Lead Sponsor
- Cancer Trials Ireland
- Target Recruit Count
- 43
- Registration Number
- NCT01566747
- Locations
- 🇮🇪
Beaumont Hospital, Dublin, Leinster, Ireland
🇮🇪Mater Misericordiae University Hospital, Dublin, Leinster, Ireland
🇮🇪Mater Private Hospital, Dublin, Leinster, Ireland
Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-03-08
- Last Posted Date
- 2021-09-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 178
- Registration Number
- NCT01548144
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue Sarcoma
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2021-01-26
- Lead Sponsor
- Heidelberg University
- Target Recruit Count
- 21
- Registration Number
- NCT01543802
- Locations
- 🇩🇪
University Hospital Heidelberg / National Centre for Tumor Diseases, Heidelberg, Germany
🇩🇪University Hospital Mannheim, Dpt. of Surgery, Mannheim, Germany
🇩🇪Klinikum Frankfurt-Höchst, Frankfurt am Main, Germany
A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies
- First Posted Date
- 2012-03-01
- Last Posted Date
- 2015-06-18
- Lead Sponsor
- New Mexico Cancer Care Alliance
- Target Recruit Count
- 3
- Registration Number
- NCT01542047
- Locations
- 🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
pazopanib_NCRCC,Ph2 STUDY
- Conditions
- Interventions
- First Posted Date
- 2012-02-24
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT01538238
- Locations
- 🇰🇷
Samsung medical Center, Seoul, Korea, Republic of
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2012-02-14
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 54
- Registration Number
- NCT01532687
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.